title: Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of moxifloxacin, a quinolone antibiotic.
abstract: The chronic toxicity and carcinogenicity of Moxifloxacin (MOX), a bacterial gyrase-inhibiting fluoroquinolone antibiotic, were studied in male and female Wistar rats in an accelerated cancer bioassay (ACB). The ACB is a mechanistic initiation/promotion chronic toxicity and carcinogenicity study designed to assess potential carcinogenic activity of a test substance in critical organs in which human carcinogens are active. The organs studied were liver, lungs, urinary bladder, mammary gland, bone marrow, thymus, spleen and stomach. MOX was given daily by intragastric instillation at 500 mg/kg bw/day for the first 13 weeks to produce potential initiation, followed by promoters (PROs) for 24 weeks, or for the last 24 weeks after 13 weeks of exposure to initiators (INs). The INs, administered during the first 13 weeks, were diethylnitrosamine for the liver, N-n-butyl-N-(4-hydroxybutyl)nitrosamine for the urinary bladder, ethylnitrosourea for the hematolymphoreticular system, N-nitrosodimethylamine for lungs, methylnitrosourea for the stomach and 7,12-dimethylbenz(a)-anthracene for the mammary gland. The PROs, administered during the last 24 weeks after MOX, were phenobarbital for the liver, nitrilotriacetic acid for the urinary bladder, azathioprine for the bone marrow, butylated hydroxytoluene for the lung, butylated hydroxyanisole for the forestomach, and diethylstilbestrol for the mammary gland. The INs produced preneoplastic and neoplastic lesions which were not enhanced by MOX, and MOX plus PROs elicited no neoplastic effects, documenting that MOX did not produce either initiation or promotion of neoplasia in any of the target sites, or in any of the other twenty tissues examined.
authors.affiliation: Department of Pathology, New York Medical College, Valhalla 10595, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Iatropoulos
authors.forename: A M
authors.initials: AM
authors.lastname: Jeffrey
authors.forename: H G
authors.initials: HG
authors.lastname: Enzmann
authors.forename: E
authors.initials: E
authors.lastname: von Keutz
authors.forename: G
authors.initials: G
authors.lastname: Schlueter
authors.forename: G M
authors.initials: GM
authors.lastname: Williams
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000633:toxicity*; D001372:Aza Compounds; D001835:Body Weight / Q000187:drug effects; D015197:Carcinogenicity Tests / Q000379:methods; D002273:Carcinogens / Q000633:toxicity*; D003043:Cocarcinogenesis; D005260:Female; D024841:Fluoroquinolones; D008297:Male; D000077266:Moxifloxacin; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D009929:Organ Size / Q000187:drug effects; D011804:Quinolines; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D002273:Carcinogens; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin